Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0248-8663(01)83655-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Boswellia Extract Promotes Healing and Resolving Inflammation in Oral Ulcers of Rat.
J Oral Pathol Med
January 2025
Department of Oral Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Background: Recurrent aphthous ulcers significantly impact patients' quality of life due to their painful and recurrent nature, necessitating more effective treatments. This study explores the therapeutic potential of Boswellia to treat recurrent aphthous ulcers by its anti-inflammatory and healing promotion effect in a rat oral ulcer model.
Methods: Network pharmacology techniques were employed to elucidate Boswellia's active components and potential targets.
Clinical efficacy of lasers in the management of recurrent aphthous ulcers of oral cavity: a systematic review of randomized control trials.
Lasers Med Sci
January 2025
College of Dentistry, Ajman University, Ajman, United Arab Emirates.
Recurrent aphthous stomatitis (RAS) is one of mankind's most common diseases with a nonspecific etiology. Lasers are gaining traction in dentistry due to their remarkable effects on pain reduction. Their convenience and lack of side effects have made them an attractive alternative to conventional interventions.
View Article and Find Full Text PDFState of knowledge of the relationship between celiac disease and oral pathology: A scoping review.
Med Oral Patol Oral Cir Bucal
January 2025
Oral Medicine, Department of Stomatology School of Dentistry, University of Granada Granada, Paseo de Cartuja s/n, 18071 Granada, Spain
Background: Celiac disease (CD) is a systemic disorder characterized by an enteropathy of highly variable clinical expression, in which the relationship with oral pathology has not yet been fully elucidated. We aimed to update the current knowledge on oral manifestations in CD, to identify evidence gaps and to point out future research lines.
Material And Methods: PRISMA-ScR guidelines were followed.
Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology.
Pharmaceutics
January 2025
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Phosphodiesterase-4 (PDE4) is involved in the synthesis of inflammatory cytokines that mediate several chronic inflammatory disorders, including psoriasis and atopic dermatitis. In recent years, the therapeutic armamentarium in dermatology has expanded with the introduction of PDE4 inhibitors, both in oral and topical formulations. PDE4 inhibitors have gained increasing interest due to their remarkable safety record and ease of prescription, as evidenced by the recent influx of literature detailing its off-label uses.
View Article and Find Full Text PDFIn Situ Gelling Dexamethasone Oromucosal Formulation: Physical Characteristics Influencing Drug Delivery.
Gels
January 2025
Department of Galenic Pharmacy, Faculty of Pharmacy, Comenius University Bratislava, Odbojárov 10, SK-832 32 Bratislava, Slovakia.
The study focuses on the development of an in situ gelling dexamethasone (DEX) oromucosal formulation designed for the treatment of aphthous stomatitis. Three series of formulations were prepared; a first series containing DEX suspended, a second series containing DEX and, in addition, mint essential oil (EO), and a third series containing EO and DEX solubilized in propylene glycol (PG). In the composition, polymers in the role of mucoadhesive agent were interchanged (hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), methyl cellulose (MC), carboxymethyl cellulose (CMC), and sodium carboxymethyl cellulose (NaCMC).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!